NHS England concludes wide-ranging deal for cystic fibrosis drugs
NHS England has today announced it has secured a definitive agreement with Vertex Pharmaceuticals to make available all three of their UK-licensed cystic fibrosis medicines.
This means NHS patients will now have full access to Orkambi, Symkevi and Kalydeco, and around 5000 people may now take up these treatments. There is no cap on patient numbers, and each and every patient in England who might benefit can now get these treatments, free on the NHS. Clinicians will be able to begin prescribing these drugs within 30 days.
NHS England has been able to finalise this negotiation because the company agreed confidential commercial terms that constitute good value for British taxpayers and agreed to submit its drugs for full NICE appraisal.
The agreement provides access to all three drugs for all current licensed indications, as well as future licence extensions too.
Announcing the agreement, NHS Chief Executive Simon Stevens said:
“The UK has the second highest prevalence of cystic fibrosis of any country in the world, so today is an important and long hoped for moment for children and adults living with cystic fibrosis.
“That fact also means that any drug company wanting to succeed commercially in this field needs to work constructively with the NHS.
“I’m pleased that Vertex has now agreed a deal that is good for our patients and fair to British taxpayers.”
NICE has also been able to back the agreement, and a binding condition of the deal is that Vertex will submit its full portfolio – including in due course its new triple therapy – to NICE for comprehensive appraisal.
The company has also agreed to a flexible commercial mechanism which will ensure continued patient access to these three medicines following completion of the NICE appraisal.
Health Secretary Matt Hancock said:
“Some wonderful news this morning. We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. The deal is great value for money for the NHS, and crucially, will improve thousands of lives. This deal – on the back of several others this summer – shows why we get some of the best value drugs in the world, and is another reason to be so proud of our NHS.”
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said:
“We are pleased an agreement has been reached between NHS England and Vertex that brings these medicines to patients. It is also welcome that the company will now re-engage with the NICE process.
“We look forward to working with the company and patient organisations to get ready for the appraisals, including developing the approach to the collection of evidence.”
Commercial terms of the agreement are confidential, but the approach achieved is consistent with NHS England’s other managed access agreements reached with the pharmaceutical industry.
Simon Stevens has today written to the chair of Parliament’s Health and Social Care Committee setting out more detail.
Investment in world-class, cutting edge technologies and treatments is at the heart of the NHS Long Term Plan. Over the last two years, as envisaged by the Accelerated Access Review, NHS England has established an expert commercial drugs team which has been working closely with industry and NICE, and has successfully negotiated a number of innovative deals, making new and promising treatments available for NHS patients. Recent such ‘smart deals’ include:
- a deal to make ocrelizumab, an innovative multiple sclerosis drug available;
- a ground-breaking deal which could eliminate Hepatitis C;
- a £300 million saving after negotiating deals with five manufacturers on low cost versions of the health service’s most costly drug, adalimumab;
- striking the first full access deal in Europe for CAR-T therapy via the Cancer Drugs Fund, which can potentially cure some children and adults with blood cancers where other treatments have failed, and;
- reaching a deal to make the life-extending lung cancer drug pembrolizumab available for routine use on the NHS
- a deal to make nusinersen available – the first treatment that targets the underlying cause of spinal muscular atrophy
Latest News from
Pre-election guidance for the 2019 General Election07/11/2019 16:15:00
This pre-election guidance will help organisations make all staff aware of the implications on communications activities of the period prior to the 2019 general election.
New NHS online training to help people get home from hospital quicker05/11/2019 16:51:00
NHS England and Health Education England have today launched ActNow, an e-learning tool developed for health service and care staff to help them reduce hospital delays for patients.
Demand for NHS burns care soars over bonfire night and diwali04/11/2019 14:15:00
Top doctors from the NHS and St John Ambulance have teamed up to urge revellers to stay safe during Guy Fawkes Night and Diwali celebrations, as new figures reveal thousands end up in hospital each year due to firework and bonfire injuries.
Public back NHS plans for new rapid care measures01/11/2019 14:25:00
England’s top doctor has welcomed new polling showing that patients and the public support NHS proposals focussing on fast treatment for those who need it in A&E.
NHS ramps up drive to increase uptake of lifesaving vaccines28/10/2019 09:15:00
More lifesaving vaccines should be provided in convenient locations for parents to drive uptake, a new NHS review shows.
Tens of thousands given life changing diabetes monitors thanks to the NHS Long Term Plan22/10/2019 14:15:00
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan.
World Antibiotic Awareness Week, 18-22 November22/10/2019 09:15:00
World Antibiotic Awareness Week (WAAW) aims to increase awareness of antibiotic resistance as a global problem, and to promote best practices among the general public, health workers and policy-makers to avoid the further emergence and spread of antibiotic resistance.
Modern screening can be more personalised and convenient to save lives says new report16/10/2019 16:15:00
The NHS has the opportunity to upgrade cancer screening to save thousands more lives each year, a major report said today.